Vitiligo is a chronic autoimmune disease that targets melanocytes, resulting in patches of skin depigmentation.  The pathogenesis of vitiligo is driven by signalling through JAK1/JAK23, and a cream formulation of ruxolitinib, a JAK1/JAK2 inhibitor,  is under investigation for the treatment of the condition.  Ruxolitinib cream provided significant repigmentation of facial vitiligo lesions after 24 weeks of double-blind, vehicle-controlled treatment (NCT03099304). 
Trial NCT03099304 was a randomised, double-blind, dose-ranging study of ruxolitinib phosphate cream in subjects with vitiligo.
Patients had to have a clinical diagnosis of vitiligo with depigmented areas including ≥0.5% of total Body Surface Area (BSA) on the face and ≥3% of total BSA on non-facial areas.
Patients in the previous groups (0.5% QD, 1.5% QD, 1.5% BID) of trial NCT03099304 continued treatment.
Subjects on vehicle and those in the 0.15% group were rerandomised if <25% improvement in facial Vitiligo Area Scoring Index (F-VASI) was seen at week 24.
Re-randomisation was to 0.5% QD, 1.5% QD, or 1.5% BID.
A total of 157 patients were studied.
Primary outcome measure
The primary endpoint was proportion of patients treated with ruxolitinib cream who achieved a ≥50% improvement from baseline in F-VASI (F-VASI50) at week 24 compared with patients treated with vehicle.
Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-17.
Rosmarin D, et al. Efficacy and safety of ruxolitinib cream for the treatment of vitiligo: results of a 24-week, randomized, double-blind, dose-ranging, vehicle-controlled study. Presented at: World Congress of Dermatology 2019.
Presented by: Prof. Kristian Reich, Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation® Center, Hamburg, Germany